The American Association of Clinical Endocrinologists (AACE) proudly showcased their new “comprehensive algorithm” for diabetes treatment at their 22nd Annual Conference in Phoenix, AZ, at the beginning of May, replacing their previous algorithm that’s been in place since 2009.
Wait, an algorithm? No, not the technology software kind. Rather, this “algorithm” is a set of complex guidelines for doctors that, according to the AACE, “considers the whole patient, the spectrum of risks and complications for…
Read more »
By
AmyT on
March 14, 2013
From the “crap no one ever tells you about with diabetes” file, comes:
Dissect the word with me for a moment:
Lipo — OK, that sounds like weight loss surgery.
Hyper — Yes, we often are. How else could we juggle work, kids, exercise, myriad lab tests and doctor’s appointments, non-stop carb-counting and dosing adjustments, etc., etc. and still do our taxes?
Trophy — Do I get one, for putting up with all this diabetes…
Read more »
Nancy Finn’s motto is that “healthcare is not a spectator sport, it is a participatory sport.” In her book, e-Patients Live Longer, The Complete Guide to Managing Health Care Using Technology, released late last year, she goes on to state:
“(Patients) should participate in decision making with their physicians, ask questions, and be willing to invest time and effort in understanding their conditions. Physicians, for their part, must be willing to share information, with their…
Read more »
By
AmyT on
September 23, 2010
Earlier this week, Novo Nordisk released results of a sweeping new survey about how patients — both type 1 and type 2 — struggle with insulin therapy, and what doctors accredit that to.
Entitled the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPPTM), the survey was conducted among almost 3,000 physicians and patients in eight countries “with the objective to learn what they perceive to be the biggest functional and emotional unfulfilled needs…
Read more »
By
AmyT on
April 16, 2010
If you can still get excited about diabetes research headlines, then here’s some exciting news coming out of Cambridge, Mass, this week: Tolerx, a life sciences company, has reported they are in Phase 3 clinical trials for a new treatment of type 1 diabetes. If everything goes to plan, a representative of the company says, Tolerx could launch the first-ever offering approved by the FDA to treat the cause of type 1 diabetes. Pretty cool!…
Read more »
